Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22759947 | 1.00 | GNAI3 (0.48) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21799804 | 0.94 | GNAI3 (0.56) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL8890431 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL18844953 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21799986 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21800093 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21799833 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21799858 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL18844935 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL1678660 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20200199282-A1 | Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-06-25 | — | — | US | disclosed |
| EP-3623398-A1 | MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION | Asahi Kasei Kabushiki Kaisha (JP) | 2020-03-18 | — | — | EP | disclosed |
| CN-110603273-A | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2019-12-20 | — | — | CN | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | GNAI3 382/4885GNAO1 539/4885GNAI1 684/4885 |
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | PDE4A, PDE4B, PDE3B | GNAI3 661/4885GNAO1 204/4885GNAI1 875/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | GNAI3 480/4885GNAO1 163/4885GNAI1 699/4885 |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | GNAI3 603/4885GNAO1 134/4885GNAI1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.